Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06917885 · ClinicalTrials.gov registry record · Phase 1
CUE-102 in Recurrent Glioblastoma
A Phase 1 study of Glioblastoma and Recurrent Glioblastoma, sponsored by David Reardon, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT06917885 is a Phase 1 study of Glioblastoma and Recurrent Glioblastoma that is actively recruiting participants, run by David Reardon, MD. The registered enrollment target is 18 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06917885, a Phase 1 study of Glioblastoma and Recurrent Glioblastoma, is actively recruiting participants, sponsored by David Reardon, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of CUE-102 for participants with Recurrent Glioblastoma (GBM). The name of the study drug involved in this study is: -CUE-102 (a type of fusion protein)
Conditions Studied
Interventions
- BIOLOGICAL CUE-102
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-07-30 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06917885
The ClinicalTrials.gov registry entry for NCT06917885 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (83% lower). The listed sponsor is David Reardon, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which CUE-102 is the first listed.
NCT06917885 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06917885 about?
NCT06917885 is a clinical study titled "CUE-102 in Recurrent Glioblastoma". The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of CUE-102 for participants with Recurrent Glioblastoma (GBM). The name of the study drug involved in this study is: -CUE-102 (a type of fusion protein)
What is the current status of trial NCT06917885?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-07-30. Estimated completion is 2028-01-31.
What conditions does trial NCT06917885 study?
This clinical trial studies the following conditions: Glioblastoma, Recurrent Glioblastoma, Glioma, Malignant.
What interventions are being tested in trial NCT06917885?
The interventions under investigation include: CUE-102 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06917885?
This trial is sponsored by David Reardon, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06917885 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
-
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.